Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,151 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
Kuter DJ, Ghanima W, Cooper N, et al. · Blood · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
Cuker A, Stauch T, Cooper N, et al. · N Engl J Med · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis.
Zhang X, Zhao Y, Yang M, et al. · Front Immunol · 2025Comparative Study, Network Meta-Analysis
- Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
Jurczak W, Chojnowski K, Mayer J, et al. · Br J Haematol · 2018Clinical Trial, Phase III, Comparative Study
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J, Arnold DM, Grossbard E, et al. · Am J Hematol · 2018Clinical Trial, Phase III, Randomized Controlled Trial
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.
Shimano KA, Grimes AB, Kaicker S, et al. · JAMA · 2025Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, et al. · Lancet · 2023Clinical Trial, Phase III, Multicenter Study
- Safety and efficacy of daratumumab in immune thrombocytopenia.
Tsykunova G, Holme PA, Tran HTT, et al. · Blood Adv · 2026Multicenter Study, Clinical Trial, Phase II
- Long-term follow-up of the STOPAGO study.
Cottu A, Guillet S, Viallard JF, et al. · Blood · 2025Clinical Trial, Multicenter Study
- A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
Chen Y, Xu Y, Li H, et al. · N Engl J Med · 2024Clinical Trial, Phase II, Clinical Trial, Phase I
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Cheng G, Saleh MN, Marcher C, et al. · Lancet · 2011Clinical Trial, Phase III, Multicenter Study
- Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM, Saleh MN, Khelif A, et al. · Blood · 2017Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial.
Wei Y, Ji XB, Wang YW, et al. · Blood · 2016Multicenter Study, Randomized Controlled Trial
- Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study.
Grace RF, Leblebisatan G, Aydinok Y, et al. · Lancet Haematol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials.
Tungjitviboonkun S, Bumrungratanayos N, Jitwimungsanon J, et al. · Ann Hematol · 2024Meta-Analysis, Review
- Laparoscopic splenectomy.
Phillips EH, Carroll BJ, Fallas MJ · Surg Endosc · 1994Clinical Trial
- Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial.
Cooper N, Ghanima W, Vianelli N, et al. · Am J Hematol · 2024Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC, Elmes JB, Arnall JR, et al. · Int Immunopharmacol · 2024Systematic Review
- [Idiopathic thrombocytopenic purpura].
Hashino S · Nihon Rinsho · 2009Systematic Review
- Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.
Mazzucconi MG, Rodeghiero F, Avvisati G, et al. · Blood Adv · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.
Cooper N, Jansen AJG, Bird R, et al. · Am J Hematol · 2025Clinical Trial, Phase II, Multicenter Study
- Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
Kuter DJ, Mayer J, Efraim M, et al. · Blood Adv · 2024Clinical Trial, Phase II, Clinical Trial, Phase I
- Safety and efficacy of baricitinib in steroid-resistant or relapsed immune thrombocytopenia: An open-label pilot study.
Zhao P, An ZY, Fu HX, et al. · Am J Hematol · 2024Clinical Trial, Phase II, Multicenter Study
- COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis.
Alharbi MG, Alanazi N, Yousef A, et al. · Expert Rev Hematol · 2022Meta-Analysis, Systematic Review
- Acute stroke in children with immune thrombocytopenia: A systematic review and meta-analysis.
Ly A, Ahmad SA, Liu O, et al. · Br J Haematol · 2025Systematic Review, Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.